David A. Siegel 4 D Molecular Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

  • $42.5 Billion
  • Q1 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023
SELL
$12.64 - $19.76 $317,845 - $496,884
-25,146 Reduced 22.38%
87,200 $1.11 Million
Q2 2023

Aug 14, 2023
BUY
$15.16 - $23.26 $187,165 - $287,167
12,346 Added 12.35%
112,346 $2.03 Million
Q1 2023

May 15, 2023
BUY
$15.45 - $23.19 $1.2 Million - $1.81 Million
77,900 Added 352.49%
100,000 $1.72 Million
Q4 2022

Feb 14, 2023
BUY
$6.85 - $25.46 $151,385 - $562,666
22,100 New
22,100 $490,000

Others Institutions Holding FDMT

# of Institutions
157
Shares Held
50.3M
Call Options Held
718K
Put Options Held
370K
View Full List

About 4D Molecular Therapeutics, Inc.

FDMT Quotes by TradingView
  • Ticker FDMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,382,400
  • Market Cap $666M
  • Description
  • 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...
More about FDMT
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email